PreeclampsiaNCT04314518
The Correlation Between Immunological Reaction of the Seminal Fluid in the Mother's Blood and Pregnancy Complications
An observational study of Preeclampsia and Pregnancy Complications, run by Sheba Medical Center at 2 sites in Israel.
Trial summary
It is known that if there isn't an efficient exposure to the paternal antigens before conception, there is an increased risk for the pre-eclampsia (PE) cascade and other pregnancy complications to take place. Read more about this study
- Who is it for?
- Ages 18 to 46 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Preeclampsia, Pregnancy Complications, Insemination; Complication
- How many people
- 100 participants
- Where
- 2 sitesIsrael
- Study dates
- 1 Nov 2020to 1 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 46 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Following immunological evaluation (as specified in sec. 3) we will prospectively follow the patients and record pregnancy outcomes. Women (from each group) will be divided into 2 sub-groups: 1. PE pregnancies and other pregnancy complications 2. Normal pregnancies In the end, we will compare between the groups and the immunology reactions at the beginning of the follow-up and see if there is a difference that is statistically significant based on the immunological results. * Women that are going through artificial insemination attend in routine follow ups in Sheba medical center that will allow continuation of follow up after the course of pregnancy. * Woman recruited to participate in the study will be marked as such by a "pop up" message appearing on their computerized medical file.
Who may be able to join
- Age 18-45
- 50 women for each group.
- Primigravid or first insemination from a new partner/sperm donor (group I)
- Women exposed to sperm (from the same donor/partner ≥ 2 times) (Group II)
- Singleton gestation
- Obtained verbal/written consent to participate in study
Who cannot join
- o Multiple gestation
- Multifetal gestation
- Chronic hypertension
- Chronic renal disease
- Autoimmune disease (antiphospholipid syndrome, systemic lupus erythematosus)
- Vascular disease
- Pregestational diabetes mellitus
Trial locations and contacts
2 sites in 1 country.
Israel2 sites, 2 recruiting
- Not yet recruiting
Sheba medical center
Ramat Gan
Natav Hendin, Medical studant, 0546899506, hendinatav@gmail.com
raanan Meir, Doctor, 0528643339, raananmeir@gmail.com
- Recruiting
Tel Hashomer Hospital
Ramat Gan
Natav Hendin, Intern, +972546899506, hendinatav@gmail.com
Raanan Meir, Doctor, +972528643339, Raanan.Meir@sheba.health.gov.il
About this study
It is known that if there isn't an efficient exposure to the paternal antigens before conception, there is an increased risk for the pre-eclampsia (PE) cascade and other pregnancy complications to take place.
It is possible that maternal immune system that doesn't develop tolerance to the paternal antigens that the seminal fluid carries, doesn't developed an adequate immune tolerance to the trophoblast cells and due to that, they are being under greater attack during placentation. Thus, the cells don't go through a normal differentiation, don't perform normal pseudo-vasculogenesis and the PE cascade is more likely to be carried out.
Read more
Both the maternal immune system and the paternal alloantigens have a role in the development of PE. Although the specific etiology remains unclear and can be only hypothesized.
In this study the investigators aim is to try and prove that there is a difference in the immunological reactions to semen prior to conception and that these changes are related to PE and/or other obstetric complications.
Hence the investigators aim to study the immune response to semen of women that will be exposed to the culprit semen for the first time compare to women that have been exposed to a culprit semen more than once previously (namely more than 1 insemination prior to the time of evaluation). After that, in a prospective cohort study the investigators would follow those women through their pregnancies and check for different pregnancy outcomes.
In this manner, the investigators are hoping to create a screening tool that will help to predict pregnancy and fetal complications before conception related to maternal immune responses of paternal antigens.
Read the detailed description
The pathophysiology of preeclampsia (PE) likely involves both maternal and fetal/placental factors. It has been established that poor placentation followed by oxidative stress/inflammation and abnormalities in the development of placental vasculature early during pregnancy may result in relative placental ischemia, which then leads to a release of antiangiogenic factors into the maternal circulation. Thus, it changes the maternal systemic endothelial function and cause hypertension and other manifestations of the disease.
Defects in spiral artery remodeling and trophoblast invasion, two related but separate processes, are characteristic of hypertensive disorders of pregnancy and fetal growth restriction. Still, the exact etiology of PE remains elusive.
In normal pregnancies, the cytotrophoblast cells of the developing placenta migrate through the decidua and part of the myometrium to invade both the endothelium and highly muscular tunica media of the maternal spiral arteries. In addition to that, they alter their adhesion molecule expression, a process referred to as pseudo-vasculogenesis.
By comparison, in PE, cytotrophoblasts fail to penetrate the myometrial segment and fail to go through pseudo-vasculogenesis.
Consequently, the spiral arteries fail to develop into large, tortuous vascular channels, resulting in placental hypoperfusion and ischemia. This defect in deep placentation has been associated with development of multiple adverse pregnancy outcomes like PE, fetal death, abruptio placentae, IUGR, Preterm labor etc.
One of the possible mechanisms responsible for defective trophoblast invasion of the spiral arteries is defective differentiation of trophoblasts. The focus on immunologic factors as a possible contributor to abnormal placental development was based, in part, upon the observation that prior exposure to paternal antigens is inversely correlated with the risk of preeclampsia. For instance, nulliparous women, women who change partners between pregnancies, have long interpregnancy intervals, use barrier contraception and conceive via intracytoplasmic sperm injection, all of which have less exposure to paternal antigens and a higher risk of developing PE. Moreover, there are also paternal contributions to PE such as a new partner, limited sperm exposure and the concept of a "dangerous father" (a father aged>45, obese and with a familial history of early-onset cardiovascular disease or hypertension). Last but not least, one of the most significant finding in this field is that donor sperm pregnancies (artificial insemination) which hold no pre-exposure to paternal antigens are much more likely to lead to PE.
In contrast, oral sex (with the father's baby) was found to protect against PE, a finding that from an immunological point of view due may be explained by the relatively greater exposure of sperm antigen to the mother immune system via the buccal mucosa.
Taking it all together the investigators assume that these putative risk factors cannot be entirely attributed to the maternal nor the paternal side, but to the encounter between those two. If there isn't an efficient exposure to the paternal antigens before conception, there is an increased risk for the PE cascade and other pregnancy complications to take place. This hypothesis can help in explaining the gap in the process that the investigators already described. It is possible that maternal immune system that doesn't develop tolerance to the paternal antigens that the seminal fluid carries, doesn't developed an adequate immune tolerance to the trophoblast cells and due to that, they are being under greater attack during placentation. Thus, they don't go through a normal differentiation, don't perform normal pseudo-vasculogenesis and the PE cascade is more likely to be carried out.
There are several immunological mechanisms that support this assumption:
- The interaction between NK cells and extra-villous trophoblast cells: In PE, conflict between maternal and paternal genes is believed to induce abnormal placental implantation through increased NK cell activity.
- HLA-G: A gene with few alleles, that can be found both in the placental interface and in the paternal seminal fluid, has a significant role in inhibiting maternal immune responses against foreign (paternal) antigens.
- Regulatory T cells (Treg): Much of present thinking seems to involve a critical role for Treg in maintaining immunological tolerance during pregnancy. It has been suggested that during evolution, a mechanism of extra-thymic differentiation of Treg emerged in the placental to enforce maternal-fetal tolerance.
Men has a clear evolutionary interest in ensuring that the immune system of his female partner accepts the semi-allogenic fetus. Due to that, he tries to "prime" the woman's immune system pre-conception.
In conclusion, it is well established that both the maternal immune system and the paternal alloantigens have a role in the development of PE. Although the specific etiology remains unclear and can be only hypothesized. Therapies should aim not to suppress the maternal immune tolerance system but rather to enhance tolerance.
In this study the investigators aim is to try and prove that there is a difference in the immunological reactions to semen prior to conception and that these changes are related to PE and/or other obstetric complications.
Hence the investigators aim to study the immune response to semen of women that will be exposed to the culprit semen for the first time compare to women that have been exposed to a culprit semen more than once previously (namely more than 1 insemination prior to the time of evaluation). After that, in a prospective cohort study the investigators would follow those women through their pregnancies and check for different pregnancy outcomes.
In this manner, the investigators are hoping to create a screening tool that will help to predict pregnancy and fetal complications before conception related to maternal immune responses of paternal antigens. If the investigators hypothesize turn out to be true, it can cause sperm banks all over the world to change their matching protocols and to test seminal fluid in the maternal blood sample before putting her through artificial insemination with a poor prognosis.
For the best of the investigator's knowledge evaluation of immunological reaction to paternal seminal fluid in the mother's blood prior conception has never been tried before.
- Conditions
- Preeclampsia, Pregnancy Complications, Insemination; Complication, Immune Tolerance, Paternal Exposure
- Keywords
- Preeclampsia, Artificial insemination, Seminal fluid, Maternal immune tolerance, Trophoblast, Vasculogenesis, Placentation, NK cells, T cells, Skin prick test
- Medical subject headings
- Pre-Eclampsia, Pregnancy Complications
What is being measured
The primary outcome is the main question the study is designed to answer.
Pregnancy complications
Pregnancy complications including PE, placental abruption, IUGR
Measured: 2 years (Anticipated)
Secondary outcomes (1)
Other pregnancy complications (Clinical or sonographic)
Sonographic indices of placental insufficiency, abortion, Intra uterine fetal death, Oligohidramnion, fetal anomalies, preterm delivery, preterm premature rupture of membranes, mode of delivery and conception success rates.
Measured: 2 years (Anticipated)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2020
- Study start1 Nov 2020
- Primary completion1 Dec 2023 (estimated)
- Study completion1 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PreeclampsiaStudies of the same condition, open and under way.
- More trials run by Sheba Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sheba Medical Center
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Natav Hendin, Medical student, Principal investigator, Sheba Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04314518
- Sponsor's protocol ID
- SHEBA-19-6226-NH-CTIL
- Status last verified
- Sep 2021
- First submitted
- 17 Mar 2020
- Last updated
- 5 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Correlation Between Immunological Reaction of the Seminal Fluid in the Mother's Blood and Pregnancy Complications
- ClinicalTrials.gov ID
- NCT04314518
- Acronym / sponsor ID
- SHEBA-19-6226-NH-CTIL
- Conditions
- Preeclampsia, Pregnancy Complications, Insemination; Complication, Immune Tolerance, Paternal Exposure
- Keywords
- Preeclampsia, Artificial insemination, Seminal fluid, Maternal immune tolerance, Trophoblast, Vasculogenesis, Placentation, NK cells
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sheba Medical CenterOther government
- Study start
- 1 Nov 2020 (actual)
- Primary completion
- 1 Dec 2023 (estimated)
- Study completion
- 1 Dec 2024 (estimated)
- First posted
- 19 Mar 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is known that if there isn't an efficient exposure to the paternal antigens before conception, there is an increased risk for the pre-eclampsia (PE) cascade and other pregnancy complications to take place.
It is possible that maternal immune system that doesn't develop tolerance to the paternal antigens that the seminal fluid carries, doesn't developed an adequate immune tolerance to the trophoblast cells and due to that, they are being under greater attack during placentation. Thus, the cells don't go through a normal differentiation, don't perform normal pseudo-vasculogenesis and the PE cascade is more likely to be carried out.
Both the maternal immune system and the paternal alloantigens have a role in the development of PE. Although the specific etiology remains unclear and can be only hypothesized.
In this study the investigators aim is to try and prove that there is a difference in the immunological reactions to semen prior to conception and that these changes are related to PE and/or other obstetric complications.
Hence the investigators aim to study the immune response to semen of women that will be exposed to the culprit semen for the first time compare to women that have been exposed to a culprit semen more than once previously (namely more than 1 insemination prior to the time of evaluation). After that, in a prospective cohort study the investigators would follow those women through their pregnancies and check for different pregnancy outcomes.
In this manner, the investigators are hoping to create a screening tool that will help to predict pregnancy and fetal complications before conception related to maternal immune responses of paternal antigens.
Detailed description
The pathophysiology of preeclampsia (PE) likely involves both maternal and fetal/placental factors. It has been established that poor placentation followed by oxidative stress/inflammation and abnormalities in the development of placental vasculature early during pregnancy may result in relative placental ischemia, which then leads to a release of antiangiogenic factors into the maternal circulation. Thus, it changes the maternal systemic endothelial function and cause hypertension and other manifestations of the disease.
Defects in spiral artery remodeling and trophoblast invasion, two related but separate processes, are characteristic of hypertensive disorders of pregnancy and fetal growth restriction. Still, the exact etiology of PE remains elusive.
In normal pregnancies, the cytotrophoblast cells of the developing placenta migrate through the decidua and part of the myometrium to invade both the endothelium and highly muscular tunica media of the maternal spiral arteries. In addition to that, they alter their adhesion molecule expression, a process referred to as pseudo-vasculogenesis.
By comparison, in PE, cytotrophoblasts fail to penetrate the myometrial segment and fail to go through pseudo-vasculogenesis.
Consequently, the spiral arteries fail to develop into large, tortuous vascular channels, resulting in placental hypoperfusion and ischemia. This defect in deep placentation has been associated with development of multiple adverse pregnancy outcomes like PE, fetal death, abruptio placentae, IUGR, Preterm labor etc.
One of the possible mechanisms responsible for defective trophoblast invasion of the spiral arteries is defective differentiation of trophoblasts. The focus on immunologic factors as a possible contributor to abnormal placental development was based, in part, upon the observation that prior exposure to paternal antigens is inversely correlated with the risk of preeclampsia. For instance, nulliparous women, women who change partners between pregnancies, have long interpregnancy intervals, use barrier contraception and conceive via intracytoplasmic sperm injection, all of which have less exposure to paternal antigens and a higher risk of developing PE. Moreover, there are also paternal contributions to PE such as a new partner, limited sperm exposure and the concept of a "dangerous father" (a father aged>45, obese and with a familial history of early-onset cardiovascular disease or hypertension). Last but not least, one of the most significant finding in this field is that donor sperm pregnancies (artificial insemination) which hold no pre-exposure to paternal antigens are much more likely to lead to PE.
In contrast, oral sex (with the father's baby) was found to protect against PE, a finding that from an immunological point of view due may be explained by the relatively greater exposure of sperm antigen to the mother immune system via the buccal mucosa.
Taking it all together the investigators assume that these putative risk factors cannot be entirely attributed to the maternal nor the paternal side, but to the encounter between those two. If there isn't an efficient exposure to the paternal antigens before conception, there is an increased risk for the PE cascade and other pregnancy complications to take place. This hypothesis can help in explaining the gap in the process that the investigators already described. It is possible that maternal immune system that doesn't develop tolerance to the paternal antigens that the seminal fluid carries, doesn't developed an adequate immune tolerance to the trophoblast cells and due to that, they are being under greater attack during placentation. Thus, they don't go through a normal differentiation, don't perform normal pseudo-vasculogenesis and the PE cascade is more likely to be carried out.
There are several immunological mechanisms that support this assumption:
- The interaction between NK cells and extra-villous trophoblast cells: In PE, conflict between maternal and paternal genes is believed to induce abnormal placental implantation through increased NK cell activity.
- HLA-G: A gene with few alleles, that can be found both in the placental interface and in the paternal seminal fluid, has a significant role in inhibiting maternal immune responses against foreign (paternal) antigens.
- Regulatory T cells (Treg): Much of present thinking seems to involve a critical role for Treg in maintaining immunological tolerance during pregnancy. It has been suggested that during evolution, a mechanism of extra-thymic differentiation of Treg emerged in the placental to enforce maternal-fetal tolerance.
Men has a clear evolutionary interest in ensuring that the immune system of his female partner accepts the semi-allogenic fetus. Due to that, he tries to "prime" the woman's immune system pre-conception.
In conclusion, it is well established that both the maternal immune system and the paternal alloantigens have a role in the development of PE. Although the specific etiology remains unclear and can be only hypothesized. Therapies should aim not to suppress the maternal immune tolerance system but rather to enhance tolerance.
In this study the investigators aim is to try and prove that there is a difference in the immunological reactions to semen prior to conception and that these changes are related to PE and/or other obstetric complications.
Hence the investigators aim to study the immune response to semen of women that will be exposed to the culprit semen for the first time compare to women that have been exposed to a culprit semen more than once previously (namely more than 1 insemination prior to the time of evaluation). After that, in a prospective cohort study the investigators would follow those women through their pregnancies and check for different pregnancy outcomes.
In this manner, the investigators are hoping to create a screening tool that will help to predict pregnancy and fetal complications before conception related to maternal immune responses of paternal antigens. If the investigators hypothesize turn out to be true, it can cause sperm banks all over the world to change their matching protocols and to test seminal fluid in the maternal blood sample before putting her through artificial insemination with a poor prognosis.
For the best of the investigator's knowledge evaluation of immunological reaction to paternal seminal fluid in the mother's blood prior conception has never been tried before.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 46 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Following immunological evaluation (as specified in sec. 3) we will prospectively follow the patients and record pregnancy outcomes. Women (from each group) will be divided into 2 sub-groups: 1. PE pregnancies and other pregnancy complications 2. Normal pregnancies In the end, we will compare between the groups and the immunology reactions at the beginning of the follow-up and see if there is a difference that is statistically significant based on the immunological results. * Women that are going through artificial insemination attend in routine follow ups in Sheba medical center that will allow continuation of follow up after the course of pregnancy. * Woman recruited to participate in the study will be marked as such by a "pop up" message appearing on their computerized medical file.
Key inclusion criteria (6 listed)
- Age 18-45
- 50 women for each group.
- Primigravid or first insemination from a new partner/sperm donor (group I)
- Women exposed to sperm (from the same donor/partner ≥ 2 times) (Group II)
- Singleton gestation
Key exclusion criteria (7 listed)
- o Multiple gestation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Pregnancy complications
Time frame: 2 years (Anticipated)
Pregnancy complications including PE, placental abruption, IUGR
1 secondary outcome
Other pregnancy complications (Clinical or sonographic)
Time frame: 2 years (Anticipated)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2022.
Related trials for Preeclampsia
RecruitingObservational study
Molecular Study of the Maternal-fetal Interface in Preeclampsia.
Preeclampsia
Recruiting
Exercise to Improve Heart and Metabolic Health After Childbirth in Women at High Risk for Preeclampsia
Postpartum Exercise, Cardiometabolic Health
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Not yet recruitingPhase 2
Furosemide vs Placebo in Severe Preeclampsia Postpartum
Severe Preeclampsia
Active, not recruitingObservational study
Validation of the MaiRa Preeclampsia Test for Screening Early/Late Preeclampsia in First and Second Trimesters
Preeclampsia (PE)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Natav Hendin, Medical student principal investigator
Sheba Medical Center
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Preeclampsia and Pregnancy Complications, run by Sheba Medical Center at 2 sites in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Natav Hendin, Medical student (0546899506, hendinatav@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pregnancy complications (time frame: 2 years (Anticipated)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2022; AzTrials last refreshed its copy on 7 Nov 2026.